33390888|t|Caffeine and Parkinson's Disease: Multiple Benefits and Emerging Mechanisms.
33390888|a|Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by dopaminergic neurodegeneration, motor impairment and non-motor symptoms. Epidemiological and experimental investigations into potential risk factors have firmly established that dietary factor caffeine, the most-widely consumed psychoactive substance, may exerts not only neuroprotective but a motor and non-motor (cognitive) benefits in PD. These multi-benefits of caffeine in PD are supported by convergence of epidemiological and animal evidence. At least six large prospective epidemiological studies have firmly established a relationship between increased caffeine consumption and decreased risk of developing PD. In addition, animal studies have also demonstrated that caffeine confers neuroprotection against dopaminergic neurodegeneration using PD models of mitochondrial toxins (MPTP, 6-OHDA, and rotenone) and expression of alpha-synuclein (alpha-Syn). While caffeine has complex pharmacological profiles, studies with genetic knockout mice have clearly revealed that caffeine's action is largely mediated by the brain adenosine A2A receptor (A2AR) and confer neuroprotection by modulating neuroinflammation and excitotoxicity and mitochondrial function. Interestingly, recent studies have highlighted emerging new mechanisms including caffeine modulation of alpha-Syn degradation with enhanced autophagy and caffeine modulation of gut microbiota and gut-brain axis in PD models. Importantly, since the first clinical trial in 2003, United States FDA has finally approved clinical use of the A2AR antagonist istradefylline for the treatment of PD with OFF-time in Sept. 2019. To realize therapeutic potential of caffeine in PD, genetic study of caffeine and risk genes in human population may identify useful pharmacogenetic markers for predicting individual responses to caffeine in PD clinical trials and thus offer a unique opportunity for "personalized medicine" in PD.
33390888	0	8	Caffeine	Chemical	MESH:D002110
33390888	13	32	Parkinson's Disease	Disease	MESH:D010300
33390888	77	96	Parkinson's disease	Disease	MESH:D010300
33390888	98	100	PD	Disease	MESH:D010300
33390888	128	154	neurodegenerative disorder	Disease	MESH:D019636
33390888	186	203	neurodegeneration	Disease	MESH:D019636
33390888	205	221	motor impairment	Disease	MESH:D000068079
33390888	366	374	caffeine	Chemical	MESH:D002110
33390888	511	513	PD	Disease	MESH:D010300
33390888	539	547	caffeine	Chemical	MESH:D002110
33390888	551	553	PD	Disease	MESH:D010300
33390888	735	743	caffeine	Chemical	MESH:D002110
33390888	789	791	PD	Disease	MESH:D010300
33390888	849	857	caffeine	Chemical	MESH:D002110
33390888	903	920	neurodegeneration	Disease	MESH:D019636
33390888	927	929	PD	Disease	MESH:D010300
33390888	940	960	mitochondrial toxins	Chemical	-
33390888	962	966	MPTP	Chemical	MESH:D015632
33390888	968	974	6-OHDA	Chemical	MESH:D016627
33390888	980	988	rotenone	Chemical	MESH:D012402
33390888	1008	1023	alpha-synuclein	Gene	6622
33390888	1025	1034	alpha-Syn	Gene	6622
33390888	1043	1051	caffeine	Chemical	MESH:D002110
33390888	1120	1124	mice	Species	10090
33390888	1152	1160	caffeine	Chemical	MESH:D002110
33390888	1216	1225	 receptor	Gene	11540
33390888	1213	1216	A2A	DNAMutation	tmVar:c|SUB|A|2|A;HGVS:c.2A>A;VariantGroup:0;OriginalGene:11540;CorrespondingGene:135;CorrespondingSpecies:10090
33390888	1227	1231	A2AR	Gene	11540
33390888	1274	1291	neuroinflammation	Disease	MESH:D000090862
33390888	1296	1310	excitotoxicity	Disease	
33390888	1420	1428	caffeine	Chemical	MESH:D002110
33390888	1443	1452	alpha-Syn	Gene	6622
33390888	1493	1501	caffeine	Chemical	MESH:D002110
33390888	1553	1555	PD	Disease	MESH:D010300
33390888	1676	1680	A2AR	Gene	135
33390888	1692	1706	istradefylline	Chemical	MESH:C111599
33390888	1728	1730	PD	Disease	MESH:D010300
33390888	1796	1804	caffeine	Chemical	MESH:D002110
33390888	1808	1810	PD	Disease	MESH:D010300
33390888	1829	1837	caffeine	Chemical	MESH:D002110
33390888	1856	1861	human	Species	9606
33390888	1956	1964	caffeine	Chemical	MESH:D002110
33390888	1968	1970	PD	Disease	MESH:D010300
33390888	2054	2056	PD	Disease	MESH:D010300
33390888	Association	MESH:D002110	MESH:D000090862
33390888	Negative_Correlation	MESH:C111599	MESH:D010300
33390888	Association	MESH:D002110	HGVS:c.2A>A;CorrespondingGene:135
33390888	Association	MESH:D015632	MESH:D010300
33390888	Negative_Correlation	MESH:D002110	MESH:D010300
33390888	Negative_Correlation	MESH:D002110	MESH:D019636
33390888	Association	MESH:D002110	11540
33390888	Negative_Correlation	MESH:D002110	6622
33390888	Negative_Correlation	MESH:C111599	135
33390888	Association	MESH:D012402	MESH:D010300

